
COA Launches Effort to Get Cancer Screenings Back on Track
Research published in November found an 85% drop in breast cancer screening and a 75% drop in colon cancer screening. Since that time, screening rates have improved somewhat.
Following a significant drop in cancer screenings as the pandemic unfolded last year, the Community Oncology Alliance (COA) today announced a partnership to promote cancer screening and catch cancer in its early stages.
The effort, “Time to Screen,” will bring COA together with
“COVID-19 has caused many people to delay recommended cancer screenings, which are now at dangerously low levels. ‘Time to Screen’ is a reminder that everyone can now do something essential for their health,” Kashyap Patel, MD, president of COA and CEO of Carolina Blood and Cancer Care in Rock Hill, South Carolina,
“It’s safer to get screened now, rather than delaying getting checked for cancer, because early detection catches cancer when it’s most treatable. It may even save your life,” he said.
Research published
This
According to COA, community oncologists report they are seeing the fallout from last year’s delayed or canceled screenings, as cancers diagnosed at later stages demand more complex treatments, resulting in higher morbidity or death. Even if cancer can be successfully treated, the regimens will cost more, which will have an impact on health care costs, especially for Medicare, experts predict.
The “Time to Screen” campaign provides assistance and educational resources, including the toll-free hotline and website featuring information on screenings for breast, colorectal, cervical, prostate, lung, and skin (melanoma) cancer.
CDC recommendations call for routine screenings for certain cancer types once people reach age 40, and those with a family history of cancer should follow specific recommendations that apply in their situations to offer the best opportunity to detect cancer at its earliest, most treatable stages.
Screening facilities are able to screen patients safely, following guidelines for COVID-19 testing, requiring face covering and social distancing, and limiting the number of people in the facility at any one time.
“Early detection of cancers through regular screenings saves lives. ‘Time to Screen’ connects Americans with local screening options and support to make appointments,” said Patricia J. Goldsmith, CEO of CancerCare. “Through this campaign we will not only be raising awareness of the importance of getting cancer screenings back on track, but also providing important support services to help overcome any barriers that individuals need to access their cancer screenings.”
The campaign will raise public awareness by engaging with local oncology practices, other medical professionals, employers, and health care purchasers. It will also involve multimedia advertising, television and radio interviews, and other strategies. Among those providing support are Bristol Myers Squibb, Genentech, Amgen, Heron Therapeutics, Incyte, Janssen, Pharmacyclics, Daiichi Sankyo Inc, Eisai Inc, EMD Serono, Merck, Pfizer, and Takeda.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.